Previous close | 77.59 |
Open | 77.31 |
Bid | 76.25 x 1800 |
Ask | 76.35 x 800 |
Day's range | 75.46 - 77.44 |
52-week range | 53.22 - 78.61 |
Volume | |
Avg. volume | 15,212,149 |
Market cap | 162.107B |
Beta (5Y monthly) | 0.48 |
PE ratio (TTM) | 26.97 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.16 (2.84%) |
Ex-dividend date | 31 Mar 2022 |
1y target est | N/A |
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
The European Commission approved J&J's (JNJ) BCMA-directed CAR-T cell therapy, Carvykti to treat patients with multiple myeloma who have already received multiple treatments.